Portfolio company COUR Pharmaceuticals announced the closing of a $50M Series B financing.
COUR Pharmaceuticals is committed to transforming the treatment of autoimmune diseases through its innovative antigen-specific immune tolerance platform, which aims to address the root causes of autoimmune dysfunction
COUR Pharmaceuticals is committed to transforming the treatment of autoimmune diseases through its innovative antigen-specific immune tolerance platform, which aims to address the root causes of autoimmune dysfunction.